- Home
- WOK vs BIVI Comparison
WOK vs BIVI Comparison
Compare WOK & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- BIVI
- Stock Information
- Founded
- WOK 2002
- BIVI 2013
- Country
- WOK China
- BIVI United States
- Employees
- WOK N/A
- BIVI N/A
- Industry
- WOK
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- WOK
- BIVI Health Care
- Exchange
- WOK NYSE
- BIVI Nasdaq
- Market Cap
- WOK 19.6M
- BIVI 18.6M
- IPO Year
- WOK 2024
- BIVI N/A
- Fundamental
- Price
- WOK $0.84
- BIVI $1.08
- Analyst Decision
- WOK
- BIVI Strong Buy
- Analyst Count
- WOK 0
- BIVI 1
- Target Price
- WOK N/A
- BIVI $30.00
- AVG Volume (30 Days)
- WOK 3.5M
- BIVI 282.1K
- Earning Date
- WOK 02-03-2025
- BIVI 05-12-2025
- Dividend Yield
- WOK N/A
- BIVI N/A
- EPS Growth
- WOK N/A
- BIVI N/A
- EPS
- WOK N/A
- BIVI N/A
- Revenue
- WOK $11,506,440.00
- BIVI N/A
- Revenue This Year
- WOK N/A
- BIVI N/A
- Revenue Next Year
- WOK N/A
- BIVI N/A
- P/E Ratio
- WOK N/A
- BIVI N/A
- Revenue Growth
- WOK N/A
- BIVI N/A
- 52 Week Low
- WOK $0.36
- BIVI $0.62
- 52 Week High
- WOK $8.45
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- BIVI 53.42
- Support Level
- WOK N/A
- BIVI $1.07
- Resistance Level
- WOK N/A
- BIVI $1.13
- Average True Range (ATR)
- WOK 0.00
- BIVI 0.06
- MACD
- WOK 0.00
- BIVI 0.00
- Stochastic Oscillator
- WOK 0.00
- BIVI 65.99
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is engaged in manufacturing and selling medical consumables through its wholly owned subsidiaries in the People's Republic of China. The Company's main products include medical face masks, tourniquets, airways, breathing circuits, intubation accessories, anesthesia kits, oxygen masks, suction sets, laryngoscope blades, KN95 masks, and other disposable medical devices, as well as medical equipment.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.